Protection against acute lung injury with EPI-hNE4 | Archives | / | Publications

Menu Content/Inhalt

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Protection against acute lung injury with EPI-hNE4

Protection against acute lung injury by intravenous or intratracheal pre-treatment with EPI-hNE4, a new potent neutrophil elastase inhibitor.
full_paper_in.pdf